Horizant (Gabapentin Enacarbil) Patent Expiration, LOE Window & CMS Spending

Horizant (Gabapentin Enacarbil) by Azurity: FDA Orange Book core substance LOE 2026-11-10 (last listed 2029-06-10), 0 AB generics, $40.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN022399 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-11-10
Last Listed Patent or Exclusivity Date2029-06-10
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40.5M
2024 Medicare Part D Spend$31.8M
2024 Medicaid Spend$8.7M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 24.3% 2-yr change)